LB Pharmaceuticals presents LB‑102 preclinical and clinical data at ECNP Congress
LB Pharmaceuticals (LBRX) presented four posters at the 39th European College of Neuropsychopharmacology (ECNP) Congress in Munich on October 10, 2026. The posters covered new preclinical evidence that LB‑102 modulates dopamine signaling via D2 autoreceptor engagement in rats, dose‑dependent cognitive improvements observed in the Phase 2 NOVA‑1 schizophrenia trial, and details of the ongoing pivotal Phase 3 NOVA‑2/NOVA‑3 program for schizophrenia and the Phase 2 ILLUMINATE‑1 trial for bipolar depression. Company officials said the data strengthen the scientific rationale for developing LB‑102 in mood disorders and address symptoms such as anhedonia.
Why it matters
The company’s statement that the new data reinforce the rationale for LB‑102 suggests potential de‑risking of its late‑stage programs, which could improve investor sentiment toward LBRX. The presentation also highlights progress in both schizophrenia and bipolar depression pipelines, informing analysts about upcoming trial readouts.
Key facts
- 1Four posters were presented on Saturday, October 10, 2026 at the ECNP Congress in Munich. stocktitan.net
- 2Preclinical data showed LB‑102 attenuates D2 autoreceptor‑mediated inhibition, increasing dopamine neurotransmission in rat nucleus accumbens. stocktitan.net
- 3A poster reported dose‑dependent, statistically significant improvements in the Global Cognition composite score in the Phase 2 NOVA‑1 schizophrenia trial. stocktitan.net
- 4The Phase 3 program (NOVA‑2 double‑blind trial and NOVA‑3 open‑label extension) is ongoing to evaluate efficacy, safety and long‑term effectiveness of LB‑102 in adults with schizophrenia. stocktitan.net
- 5An e‑poster described the design of the Phase 2 ILLUMINATE‑1 trial assessing LB‑102 monotherapy in adults with bipolar I depression. stocktitan.net
- 6Company Chief Medical Officer Susan G. Kozauer said the data strengthen the scientific rationale for LB‑102 in mood disorders and may address anhedonia. stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.